the cancer therapeutics innovation pipeline (ctip) program was established to capitalize on ontario’s expertise in cancer biology and drug discovery. its aim is to create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) to attract partnerships and/or investment for further preclinical and clinical development. to generate a sustainable pipeline, ctip will support projects that aim to provide increasing evidence of target validation and disease association using data from knowledge bases, functional assays, and drug screening in relevant in vitro and in vivo models of the cancer type of interest.

ctip funds projects in four stages of preclinical drug discovery and is currently inviting applications for the following two funding streams:

early validation projects: deliver robust translational evidence that a target-of-interest (toi) is associated with a specific cancer type(s) based on data from knowledge bases and from studies demonstrating that perturbation of the toi in relevant cell-based models produces anti-cancer effects sufficient to trigger a drug discovery campaign.

funding available: up to $150,000 per year for a maximum of two years.

early accelerator projects: deliver a validated primary assay to enable initial screening of molecules against a defined target. preliminary evidence of linearity of results between the primary assay and supporting secondary assays under development is also required. 

funding available: up to $150,000 for a maximum of one year.

the cihr institute of circulatory and respiratory health (cihr-icrh) and the canadian cardiovascular society (ccs) have partnered on an annual distinguished lecturer award in cardiovascular sciences in recognition of an individual's outstanding contribution to the advancement of cardiovascular sciences both in canada and internationally. the award will be presented to the selected candidate at the canadian cardiovascular congress (ccc) october 24-27th in vancouver bc, where the recipient will be invited to participate in a session as a part of the scientific program. ccc is the largest gathering of cardiovascular and allied health professionals in canada.

the selected candidate will be an outstanding scientist who has conducted the majority of their research in canada and contributed significantly to the advancement of cardiovascular sciences. the individual may have conducted work in any one of a number of cardiovascular disciplines and within any of the four cihr research theme areas: biomedical; clinical; health systems and services; or, social, cultural, environmental and population health. the nominated candidate's research should also be in a field of interest to the cihr-icrh, ccs, and attendees of the ccc.

the cihr institute of circulatory and respiratory health (cihr-icrh) and the canadian cardiovascular society (ccs) have partnered on an annual mid-career lecturer award in cardiovascular sciences in recognition of an individual's outstanding contribution to the advancement of cardiovascular sciences in canada at the mid-point of their career. the award will be presented to the selected candidate at the canadian cardiovascular congress (ccc) – october 24-27, 2024 in vancouver, where the recipient will be invited to participate in a session as part of the scientific program. ccc is the largest gathering of cardiovascular and allied health professionals in canada.

the selected candidate will be an outstanding mid-career investigator (at the time of application, has assumed their independent research position 5-15 years ago) who has conducted the majority of their research in canada and contributed significantly to the advancement of cardiovascular sciences. for the 2024 competition only, the eligibility time frame is adjusted by 1 year to account for productivity losses as a result of the covid-19 pandemic. as such, the eligibility time frame is from 6-16 years ago. for all competitions, we will account for all disclosed leaves (i.e. parental, medical, and family responsibility leave) when calculating career stage.

the brain health medicines scholar award provides funding and drug development support to researchers whose work aims to treat, prevent or cure alzheimer's disease and related dementias. the award includes:

• one-year grant
• $100,000 with appropriate justification 
• potential to renew for a second year based on milestones achieved 
• dedicated project manager for the duration of the award
• drug development, commercial strategy and business development support from harrington's therapeutics development center experts
• opportunity to quality for up to $400,000 in additional funding and drug development support

for more information, please contact jill sherman at intl.research@lakeheadu.ca.

the alzheimer's drug discovery foundation (addf) and harrington discovery institute provide funding and drug development support of research efforts that aim to treat or prevent alzheimer’s disease, related dementias and cognitive-decline associated with aging. each year up to two addf-harrington scholars are chosen. the award includes:

two-year grant
funding up to $600,000
opportunity to qualify for investment funds
drug development expertise and project management support
a personalized team of drug developers and project manager for each award recipient
expert business, commercialization and clinical development advice
regulatory assistance
intellectual property (ip) review and advice

the green construction through wood (gcwood) program encourages the use of innovative wood-based building technologies in construction projects. this program supports canada’s commitment to reach 2030 and 2050 emissions reduction targets under the paris agreement and advance long-term priorities regarding greenhouse gas (ghg) emissions reduction.

gcwood invests in wood construction projects that generate many benefits, including:

• reduced ghg emissions from renewable and sustainable resources that help decarbonize the built environment
• accelerated adoption of innovative building technologies and systems
• updated building codes that allow for taller and larger wood buildings
• affordable housing and community infrastructure

the battery industry acceleration call, delivered under natural resources canada’s (nrcan) energy innovation program (eip), will support technologies that accelerate battery value chain decarbonization, security, and competitiveness for canada. the call will also contribute to federal efforts to strengthen the network of canadian battery innovators to help grow world-class canadian firms in the battery value chain.

this funding call is open to research and development, or demonstration projects focused on the following four elements of the battery value chain:

• materials (anode and cathode active materials and precursors)
• components (electrolyte, current collectors, additives, etc.)
• cell
• pack